Published in J Natl Cancer Inst on April 11, 2011
Systems biology of cisplatin resistance: past, present and future. Cell Death Dis (2014) 1.74
Genome-wide association study of survival in patients with pancreatic adenocarcinoma. Gut (2012) 1.66
Genome-wide meta-analysis identifies variants associated with platinating agent susceptibility across populations. Pharmacogenomics J (2011) 1.09
Comprehensive characterization of cancer subtype associated long non-coding RNAs and their clinical implications. Sci Rep (2014) 1.08
Genome-wide association study of prognosis in advanced non-small cell lung cancer patients receiving platinum-based chemotherapy. Clin Cancer Res (2012) 1.05
Genome-wide association study identifies common variants in SLC39A6 associated with length of survival in esophageal squamous-cell carcinoma. Nat Genet (2013) 1.04
Genetic susceptibility to lung cancer and co-morbidities. J Thorac Dis (2013) 1.02
Meta-analysis on pharmacogenetics of platinum-based chemotherapy in non small cell lung cancer (NSCLC) patients. PLoS One (2012) 0.99
MicroRNA-related genetic variants associated with clinical outcomes in early-stage non-small cell lung cancer patients. Cancer Res (2013) 0.98
Implications of genome-wide association studies in cancer therapeutics. Br J Clin Pharmacol (2013) 0.96
Genome-wide association study of genetic predictors of overall survival for non-small cell lung cancer in never smokers. Cancer Res (2013) 0.96
Germline polymorphisms in an enhancer of PSIP1 are associated with progression-free survival in epithelial ovarian cancer. Oncotarget (2016) 0.90
Circulating levels of immune and inflammatory markers and long versus short survival in early-stage lung cancer. Ann Oncol (2013) 0.89
Polymorphisms in MicroRNAs are associated with survival in non-small cell lung cancer. Cancer Epidemiol Biomarkers Prev (2014) 0.88
Association between CASP8 and CASP10 polymorphisms and toxicity outcomes with platinum-based chemotherapy in Chinese patients with non-small cell lung cancer. Oncologist (2012) 0.85
SSBP2 variants are associated with survival in glioblastoma patients. Clin Cancer Res (2012) 0.79
TNFRSF10B polymorphisms and haplotypes associated with increased risk of death in non-small cell lung cancer. Carcinogenesis (2013) 0.78
Cytochrome P450 Allele CYP3A7*1C Associates with Adverse Outcomes in Chronic Lymphocytic Leukemia, Breast, and Lung Cancer. Cancer Res (2016) 0.78
The study of the relation of DNA repair pathway genes SNPs and the sensitivity to radiotherapy and chemotherapy of NSCLC. Sci Rep (2016) 0.77
Single nucleotide polymorphisms (SNPs) in non-small cell lung cancer (NSCLC) patients. Oncologist (2012) 0.77
Inflammation-related genetic variations and survival in patients with advanced non-small cell lung cancer receiving first-line chemotherapy. Clin Pharmacol Ther (2014) 0.77
Interleukin polymorphisms associated with overall survival, disease-free survival, and recurrence in non-small cell lung cancer patients. Mol Carcinog (2015) 0.75
Advanced squamous lung carcinoma in a patient experiencing long-term survival following repeated responses to gemcitabine and cisplatin chemotherapy: A case report. Oncol Lett (2015) 0.75
A 19-Gene expression signature as a predictor of survival in colorectal cancer. BMC Med Genomics (2016) 0.75
Inherited variation in the ATP-binding cassette transporter ABCB1 and survival after chemotherapy for stage III-IV lung cancer. J Thorac Oncol (2014) 0.75
Driver genes in non-small cell lung cancer: Characteristics, detection methods, and targeted therapies. Oncotarget (2017) 0.75
Genetic Determination of Serum Levels of Diabetes-Associated Adipokines. Rev Diabet Stud (2016) 0.75
Germline genetic variants and lung cancer survival in African Americans. Cancer Epidemiol Biomarkers Prev (2017) 0.75
PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet (2007) 209.92
Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics (2004) 125.23
Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet (2006) 115.71
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med (2002) 24.87
A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature (2008) 18.21
Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat Genet (2008) 16.17
A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature (2008) 16.10
Cumulative association of five genetic variants with prostate cancer. N Engl J Med (2008) 15.34
Stromal gene expression predicts clinical outcome in breast cancer. Nat Med (2008) 10.68
Lung cancer susceptibility locus at 5p15.33. Nat Genet (2008) 5.99
Common 5p15.33 and 6p21.33 variants influence lung cancer risk. Nat Genet (2008) 5.43
Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J Exp Med (2003) 3.91
Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. Chest (2005) 3.51
Identification of genetic variants contributing to cisplatin-induced cytotoxicity by use of a genomewide approach. Am J Hum Genet (2007) 3.05
Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol (2008) 3.03
Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology (2007) 3.01
XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol (2004) 2.93
Assessment of clinical validity of a breast cancer risk model combining genetic and clinical information. J Natl Cancer Inst (2010) 2.82
Heritability and linkage analysis of sensitivity to cisplatin-induced cytotoxicity. Cancer Res (2004) 2.10
Chemerin--a new adipokine that modulates adipogenesis via its own receptor. Biochem Biophys Res Commun (2007) 2.00
VPS10P-domain receptors - regulators of neuronal viability and function. Nat Rev Neurosci (2008) 1.98
Identification of chemerin receptor (ChemR23) in human endothelial cells: chemerin-induced endothelial angiogenesis. Biochem Biophys Res Commun (2009) 1.74
Resolvin E1 receptor activation signals phosphorylation and phagocytosis. J Biol Chem (2009) 1.50
Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res (2008) 1.46
Genetic variation in the DNA repair genes is predictive of outcome in lung cancer. Hum Mol Genet (2007) 1.32
Susceptibility loci involved in cisplatin-induced cytotoxicity and apoptosis. Pharmacogenet Genomics (2008) 1.26
Akt involvement in paclitaxel chemoresistance of human ovarian cancer cells. Ann N Y Acad Sci (2007) 1.23
The three sorCS genes are differentially expressed and regulated by synaptic activity. J Neurochem (2004) 1.21
Role of chemerin/CMKLR1 signaling in adipogenesis and osteoblastogenesis of bone marrow stem cells. J Bone Miner Res (2010) 1.13
Tumour necrosis factor alpha-converting enzyme mediates ectodomain shedding of Vps10p-domain receptor family members. Biochem J (2006) 1.13
Identification of SorCS2, a novel member of the VPS10 domain containing receptor family, prominently expressed in the developing mouse brain. Mech Dev (2001) 1.10
Functional organization of the sortilin Vps10p domain. J Biol Chem (2004) 1.05
Germline genetic variations in drug action pathways predict clinical outcomes in advanced lung cancer treated with platinum-based chemotherapy. Pharmacogenet Genomics (2008) 1.05
The genes for the human VPS10 domain-containing receptors are large and contain many small exons. Hum Genet (2001) 1.03
Xeroderma pigmentosum group D haplotype predicts for response, survival, and toxicity after platinum-based chemotherapy in advanced nonsmall cell lung cancer. Cancer (2006) 1.02
Pharmacogenomics of platinum-based chemotherapy in NSCLC. Expert Opin Drug Metab Toxicol (2009) 0.97
Gene expression differences in normal esophageal mucosa associated with regression and progression of mild and moderate squamous dysplasia in a high-risk Chinese population. Cancer Res (2006) 0.94
Prediction of lymphatic metastasis based on gene expression profile analysis after brachytherapy for early-stage oral tongue carcinoma. Radiother Oncol (2008) 0.88
In vitro pharmacogenomic database and chemosensitivity predictive genes in gastric cancer. Genomics (2008) 0.84
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
The influence of finasteride on the development of prostate cancer. N Engl J Med (2003) 24.45
Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med (2010) 22.74
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol (2012) 22.04
International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol (2011) 21.49
Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med (2013) 19.87
A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature (2009) 18.39
The mutational landscape of head and neck squamous cell carcinoma. Science (2011) 16.88
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat Genet (2008) 16.17
A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature (2008) 16.10
Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med (2004) 15.10
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature (2012) 14.33
A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am J Hum Genet (2004) 13.71
Lung cancer. N Engl J Med (2008) 13.49
Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med (2009) 13.47
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst (2005) 13.00
TRAF1-C5 as a risk locus for rheumatoid arthritis--a genomewide study. N Engl J Med (2007) 12.24
Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA (2011) 11.02
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet (2008) 10.74
Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nat Genet (2010) 9.90
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature (2012) 9.89
STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med (2007) 9.80
The origin and evolution of mutations in acute myeloid leukemia. Cell (2012) 9.66
Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc (2008) 8.94
Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. J Clin Oncol (2004) 8.83
Genomic sequence of the pathogenic and allergenic filamentous fungus Aspergillus fumigatus. Nature (2005) 8.55
BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res (2002) 8.55
Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. J Clin Oncol (2004) 8.15
Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature (2012) 8.03
The knockout mouse project. Nat Genet (2004) 7.80
Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet (2012) 7.61
The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov (2011) 7.57
SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet (2009) 7.48
Shifting paradigm of association studies: value of rare single-nucleotide polymorphisms. Am J Hum Genet (2008) 7.36
Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol (2008) 7.35
Common variants at CD40 and other loci confer risk of rheumatoid arthritis. Nat Genet (2008) 7.07
Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med (1991) 6.39
Lung cancer susceptibility locus at 5p15.33. Nat Genet (2008) 5.99
Functional variants of OCTN cation transporter genes are associated with Crohn disease. Nat Genet (2004) 5.83
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet (2012) 5.64
A genome-wide association study of lung cancer identifies a region of chromosome 5p15 associated with risk for adenocarcinoma. Am J Hum Genet (2009) 5.62
Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins. Cancer Res (2004) 5.57
Common 5p15.33 and 6p21.33 variants influence lung cancer risk. Nat Genet (2008) 5.43
Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med (2014) 5.37
Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins. Arthritis Rheum (2005) 5.18
Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility. Nat Genet (2009) 5.13
Telomere dysfunction: a potential cancer predisposition factor. J Natl Cancer Inst (2003) 5.09
Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. J Clin Invest (2009) 5.07
A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature (2012) 5.02
A functional variant of SUMO4, a new I kappa B alpha modifier, is associated with type 1 diabetes. Nat Genet (2004) 4.95
Novel mutations target distinct subgroups of medulloblastoma. Nature (2012) 4.82
Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. J Clin Oncol (2013) 4.72
Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature (2007) 4.70
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet (2012) 4.70
Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst (2007) 4.64
Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS One (2009) 4.62
High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis. Nat Genet (2012) 4.46
Exposure to diesel motor exhaust and lung cancer risk in a pooled analysis from case-control studies in Europe and Canada. Am J Respir Crit Care Med (2010) 4.35
Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res (2005) 4.25
A risk model for prediction of lung cancer. J Natl Cancer Inst (2007) 4.25
The PhenX Toolkit: get the most from your measures. Am J Epidemiol (2011) 4.19
Statins and cancer prevention. Nat Rev Cancer (2005) 4.12
Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst (2007) 4.07
Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev (2006) 4.02
Validation of an accelerated 'demons' algorithm for deformable image registration in radiation therapy. Phys Med Biol (2005) 4.00
Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res (2005) 3.98
PTPN22 genetic variation: evidence for multiple variants associated with rheumatoid arthritis. Am J Hum Genet (2005) 3.95
Second-line treatment of advanced non-small cell lung cancer. J Thorac Oncol (2008) 3.95
A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat Genet (2010) 3.93
Multiple independent loci at chromosome 15q25.1 affect smoking quantity: a meta-analysis and comparison with lung cancer and COPD. PLoS Genet (2010) 3.91
Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol (2012) 3.89
Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol (2007) 3.88
Gene expression signature of cigarette smoking and its role in lung adenocarcinoma development and survival. PLoS One (2008) 3.87
Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep (2013) 3.85
Ignoring linkage disequilibrium among tightly linked markers induces false-positive evidence of linkage for affected sib pair analysis. Am J Hum Genet (2004) 3.83
Interlaboratory comparability study of cancer gene expression analysis using oligonucleotide microarrays. Clin Cancer Res (2005) 3.79
Characterization of BRCA1 and BRCA2 mutations in a large United States sample. J Clin Oncol (2006) 3.73
Screening the genome for rheumatoid arthritis susceptibility genes: a replication study and combined analysis of 512 multicase families. Arthritis Rheum (2003) 3.73
Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. N Engl J Med (2009) 3.70
Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet (2012) 3.69